INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive malignancy arising from the mesothelial cells lining the pleura. This tumor was once rare, but its incidence is increasing worldwide, probably as a result of widespread exposure to asbestos, which is the principal risk factor. 1) Because of the long latency period between asbestos exposure and the development of MPM, the annual incidence is expected to increase during the next 20 years, depending on the level of asbestos exposure between 1965 and 1980.
Extrapleural pneumonectomy (EPP) alone does not improve the 2-year survival rate of 10% to 33%. [2] [3] [4] Currently, combined modality approaches including surgery, radiation, and chemotherapy are regarded as the standard of care in patients with resectable MPM. 5) Although combined modality treatment has been reported to improve the local control and survival rate, 6, 7) local recurrence is still the most common site of first relapse. 8) On the other hand, there is evidence that a higher radiation dose can improve the local control rate. [9] [10] [11] However, there are two significant limitations for dose escalation with conventional three-dimensional conformal radiotherapy. First, the post-EPP space is irregularly shaped, and it is difficult to deliver conformal doses to irregularly shaped targets. In particular, the presence of the posterior diaphragmatic sulcus, which may reach as far posteriorly as the L2 vertebra, makes it difficult to give adequate radiation doses to this region using conventional techniques.
12) Sec-ond, there are the proximity of dose-limiting critical structures such as the spinal cord, liver, kidneys, esophagus, heart, and contralateral lung. Conventional radiotherapy to the hemithorax and mediastinum is limited by the ability of these organs to tolerate radiation, as well as by the total volume of tissue being irradiated. Intensity-modulated radiation therapy (IMRT) has the potential to conform radiation doses tightly to irregularly shaped targets and might be better able to spare adjacent normal tissue compared with conventional approaches. Helical tomotherapy is a new promising and special instrument for administering IMRT. Several planning studies showed that helical tomotherapy could realize sharper dose gradients and better sparing of the organs at risk compared with step-and-shoot IMRT or stereotactic radiotherapy. [13] [14] [15] [16] Because the clinical target volume (CTV) in postoperative MPM is especially irregular and surrounded by dose-limiting critical structures, helical tomotherapy is thought to be suitable for postoperative IMRT for MPM. However, postoperative hemithoracic IMRT remains experimental due to a high incidence of fatal pneumonitis. [17] [18] [19] [20] [21] Therefore, we planned a Phase I dose escalation study for hemithoracic IMRT using helical tomotherapy. We herein describe the initial findings using the new technique and the results of treatment of the first three patients with MPM after EPP because this technique may provide benefits to such patients.
MATERIALS AND METHODS

Design of the phase I study
A Phase I dose-escalation study was planned for patients with ipsilateral intrathoracic recurrence after pneumonectomy of thoracic malignancies (lung cancer, mediastinal tumors and MPM) or in post-EPP status of MPM. Additionally, eligible patients were required to be 1) at least 6 weeks after surgery and at least 4 weeks after chemotherapy; 2) aged between 20 years and 74 years; 3) to have a performance status (PS) of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale; 4) to have adequate bone marrow reserve, normal liver function, normal renal function and normal pulmonary function; and 5) to have a life expectancy of 12 weeks or more. Patients were excluded if they had a severe or uncontrolled concomitant illness, active infection, were pregnant or breastfeeding, or had interstitial pneumonitis, pulmonary fibrosis or severe heart disease.
The radiation dose prescription was defined to cover 95% of the planing target volume. The prescription was designed to escalate doses as 45.0 Gy in 25 fractions, 50.4 Gy in 28 fractions, and 54.0 Gy in 30 fractions. The target doses to PTV and the dose constraints for organs at risk (OARs) are given in Table 1 . The dose was escalated according to the frequency of dose limiting toxicity (DLT) evaluated during 6 months after the start of IMRT. DLT was defined as: (1) Grade 3 or worse nonhematological toxicities; (2) Grade 4 hematological toxicities; (3) any unresolved toxicity requiring discontinuation of therapy exceeding 10 days. Toxicities were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. 22) At least 3 patients were enrolled at each dose level. The local ethics committee approved the study (UMIN000004066) and written informed consent was obtained from all patients.
Treatment planning
Patients were immobilized in the supine position using a Vac-lock bag (Med-Tec, Orange City, Iowa) with their arms above their head. The treatment planning was based on a 5 mm thickness, and 5 mm interval computed tomography (CT) scans. The CT images were obtained under normal quiet breathing through the all images. Contours for targets and organs at risk were drawn with the FOCAL 4.3.1 program (CMS, St. Louis, MO). The CTV was defined as the entire preoperative ipsilateral hemithorax pleural space, scars, drain sites, and involved nodal stations: the superior border was 5 mm superior to the most superior surgical bed (usually just above the first rib); the anterior, posterior, and lateral margins were 3-5 mm beyond to the inside of the thorax or skin if near a surgically violated space; particular attention was directed to defining the posteroinferior extent of the CTV to include the insertion of the diaphragm, which was often in the vicinity of the L2. The PTV was bound to the external surface of the body outline. The following normal tissues were defined as organs at risk (OAR): the spinal cord, contralateral lung, each kidney (separately), liver, small bowel, stomach, esophagus and heart. The CTV were generally expanded by 5 mm to a PTV, which was clipped on the body outline. The IMRT plans were generated with the Hi-Art tomotherapy planning system version 3.1.5.3 software program (Madison, Wisconsin, USA) based on superposition/convolution calculation algorithm. 23) A longitudinal field width of 2.5 cm and a pitch of 0.287 were chosen. The intensity modulation factor (IMF), which is defined as the ratio of the maximum leaf intensity and average leaf intensity ignoring leaves with zero intensity per projection, was set at 2.50, which resulted in a used IMF of 1.99 on average.
Dosimetric evaluation in the organs at risk
The present plans were compared to two recent planning studies addressing the hemithoracic IMRT after EPP in the organs at risk using DVH parameters. 24, 25) Sterzing et al. 24) and Scorsetti et al. 25) evaluated the data from 10 patients (5 right-and 5 left-sided MPM) and the data from 6 patients (3 right-and 3 left-sided MPM), respectively. Because the prescription doses were different in each plan, the DVH findings were normalized by the prescription doses ratio. The plans generated by Sterzing et al. were normalized to a median dose of 54 Gy to the PTV. The corresponding dose of the present plans was 45.5 Gy. The plans generated by Scorsetti et al. were normalized to a mean dose of 54 Gy to the PTV. A corresponding dose of the present plans was 45.4 Gy. Namely, the normalized DVH findings were defined as follows:
Normalized DVH findings = A * 45.5/54 or 45.4/54 with A being the corresponding finding.
RESULTS
Patient data
From February 2009 to July 2010, 3 patients with postoperative MPM were enrolled in this study. All of them entered at dose level of 45 Gy. The patients' characteristics are listed in Table 2 . All patients had received intra-thoracic chemotherapy with cisplatin before EPP. Case 1 had recurrent MPM after EPP. He had received chemotherapy with cisplatin and pemetrexed, followed by IMRT for the hemithorax. The remaining patients also had MPM and received hemithoracic IMRT as adjuvant therapy after neoadjuvant chemotherapy with cisplatin and pemetrexed, followed by EPP.
Treatment data
The individual dosimetric data are provided in Table 3 . The dose-volume constraints for normal tissue were met in all cases. None of the patients reached the optimal parameter of the esophagus V55 because the prescribed dose was relatively small (45 Gy). The representative dose distribution in the axial view and dose-volume histogram are demonstrated in Figs. 1 and 2 . planning studies addressing the role of IMRT or helical tomotherapy in the treatment of MPM. The lung V5s of the present plans was smaller than that of the planning studies, while the lung V20s of the present plans were larger than those of the planning studies. The mean lung dose of the present plans was similar to that of the planning studies. The dosimetric findings of the liver, bilateral kidneys and heart were similar to those of the planning studies. The dosimetric findings of the spinal cord and esophagus, especially each mean dose, were larger than those of the planning studies.
Dosimetric evaluation in the organs at risk
Toxicity and follow-up
The follow-up period of each patient was 26, 14 and 9 months from IMRT, respectively. All patients were alive at the last follow-up. Of the three patients, 1 patient (case 2) developed local recurrence and pleural dissemination in the contralateral lung. Only 1 patient (case 1) had Grade 2 acute esophagitis and nausea. There was no treatment-related pneumonitis. 
DISCUSSION
This is the first report of MPM patients actually treated by IMRT using helical tomotherapy after EPP. IMRT can provide a highly conformal dose to irregularly shaped targets and a steep dose gradient near the critical structures, which may improve locoregional tumor control through dose escalation while maintaining acceptable dose levels of the critical structures. However, postoperative IMRT for MPM remains experimental due to a high incidence of fatal pneumonitis. Allen et al. reported that after completion of therapy, 6 of 13 patients (46%) developed fatal pneumonitis. 17) At the University of Texas M.D. Anderson Cancer Center, 63 patients with malignant mesothelioma were treated by EPP and IMRT. The incidence of fatal pulmonary complications within 6 months after IMRT was 10%. 18, 19) Miles et al. demonstrated that 1 of 13 patients died of fatal pulmonary toxicity after IMRT following EPP. 20) At Copenhagen University Hospital/Rigshospitalet, 26 patients were treated with induction chemotherapy followed by EPP and IMRT.
Of these, 4 patients (15%) experienced fatal pulmonary toxicity. 21) Moreover, their data suggested that a radiation dose as low as 5 Gy (V5; volume of lung receiving 5 Gy or more and VS5; volume of lung spared exposure to doses of 5 Gy or more) seemed to be a major contributor, in addition to the MLD and V20, to determining the tolerance levels. These reports showed that the median V5 for the patients with fatal pulmonary toxicity was greater than that for the patients without fatal pulmonary toxicity (92.0%-98.6% vs. 66.0%-94.1%). Because the patients had received chemotherapy and experienced major surgical stress before radiotherapy, the established statistics and normal tissue complication probabilities [26] [27] [28] could not be simply referred to regarding these patients.
The helical delivery of irradiation by tomotherapy was also feared to expose a larger lung volume to low doses of irradiation. In terms of lung volumes receiving lower doses, step-and-shoot IMRT has usually been superior to helical tomotherapy in lung cancer patients. 29) Against this background, a Phase I dose escalation study of hemithoracic IMRT was conducted for postoperative Abbreviations: SS = step-and-shoot; SW = sliding window; IMF = intensity modulation factor; * = data of left-sided MPM patients; # = dose received by 1% of volume (D1%).
MPM using helical tomotherapy, which is capable of improving the target volume and homogeneity while sparing organs at risk. The V5s of the present plans were smaller than those expected from the past literature. However, this comparison requires careful interpretation, because the dose prescription and patient characteristics, including the tumor location and extension were different among the plans. For this reason, the dosimetric findings for the present plans were compared with those for the recent planning studies, in which the dose prescriptions were similar to that of the present plans, and the dosimetric findings were normalized to the prescription dose. However, even in comparison to the dosimetric findings of the recent planning studies, the V5s of the present plans was smaller than that of the recent planning studies. In contrast, the mean lung dose and lung V20 were not smaller than those of the recent studies. On the other hand, the dosimetric findings of the spinal cord and esophagus were larger than those of the planning studies. These findings suggest that the intention to lower the lung dose resulted in increases in the spinal cord and esophagus doses. The liver dose evaluation was difficult to perform because all of the current cases presented with left thoracic lesions. Sterzing et al. simulated IMRT by helical tomotherapy in the adjuvant treatment of MPM and compared the target homogeneity, conformity and normal tissue dose with stepand-shoot IMRT. 24) Two different tomotherapy plans were created with different IMFs. The target homogeneity and coverage could be significantly improved with tomotherapy plans. The lung V5 in helical tomotherapy with low IMF plans were statistically higher than for step-and-shoot IMRT, while with high IMF plans, the V5 were statistically lower than for step-and-shoot IMRT. The IMF for the low and high groups was 1.22 and 2.23 on average, respectively. The average of our plans' IMF was 1.99. Therefore, our plans could be assessed as high-intensity modulation plans. It is important to use high IMF for a highly conformal dose distribution and a steep dose gradient near critical structures.
Before IMRT was introduced, postoperative hemithoracic radiotherapy was performed using a combination of photons and electrons. Electron beams were used to supplement the photon-blocked regions. For example, photons treat most of the hemithoracic field, but blocks are needed to spare critical structures. Electrons treat the superficial tissues and spare the deeper critical organs. 30, 31) However, with this approach, the matching of photon and electron beams is difficult, and poor matching often caused cold and hot spots in the junction area. These cold spots may have a higher likelihood for local recurrence. Gupta et al. reported 86 patients with MPM who underwent EPP followed by hemithoracic radiation therapy using a combination of photons and electrons (median dose: 54 Gy). Of the 78 analyzed patients, 15 patients failed in local and/or nodal sites. 32) Of these 15 patients, 10 failed in the regions of dose inhomogeneity. They concluded that the photon-electron technique was tolerable, but that IMRT may provide better target coverage in some patients.
Chana et al. presented a new method for treating MPM utilizing a combination of static electron fields and IMRT (IMRT+e). 33) As compared with IMRT, IMRT+e can better spare the critical structures. However, the difficulty of matching the photon and electron beams is unresolved, because the electron fields were manually chosen to balance target coverage and normal tissue protection. We therefore consider that IMRT without an electron beam is beneficial for hemithoracic radiation therapy.
Finally, the limitations associated with the present study need to be addressed. First of all, this study evaluated only 3 cases with a short follow-up period and further investigations with an increased number of cases and a long-term follow-up are mandatory. Another limitation is that all cases had left thoracic lesions. Therefore, the evaluation of radiation induced liver damage is difficult because the liver dose in the present cases is generally smaller than that used for the treatment of right thoracic lesions. Even though these limitations into account, IMRT using helical tomotherapy is considered to induce only mild adverse events and this technique may therefore be beneficial for the management of such MPM patients.
